NEOG — NEOGEN CORP

Nasdaq · Health Care · Life Sciences Tools & Services · CIK 711377 ·
Last close
$11.60
Market Cap
$2.53B
52W High
$12.85
52W Low
$8.63
ADV30
2,080,187
Next earnings
2026-10-08
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns for food producers and processors. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems used for administering antibiotics and vaccines under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin, used in dogs to assist in managing pyoderma; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis on the results from multiple locations over extended periods. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
May 2026 225,300,000 107,800,000 3,100,000 -11,300,000 3,346,000,000 185,500,000 1,253,100,000
Feb 2026 211,200,000 99,000,000 -3,300,000 -17,000,000 3,359,000,000 159,900,000 1,256,600,000
Nov 2025 224,691,000 106,684,000 -5,377,000 -15,924,000 3,359,953,000 145,340,000 1,255,465,000
Aug 2025 209,189,000 94,970,000 -16,091,000 36,338,000 3,378,156,000 138,883,000 1,259,507,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$83,200,000
Investing CF
$70,500,000
Financing CF
$-99,400,000
CapEx
$-51,300,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.80
As of
2026-08-02

Balance + Analyst (yfinance extras)

Retained Earnings
$-544,300,000
Inventory
$144,300,000
Receivables
$146,800,000
ST Investments
$0
EBIT TTM
$50,134,000
Pretax Income TTM
$-8,956,000
Interest Exp TTM
$59,090,000
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$870,400,000
EBITDA
$94,700,000
Free Cash Flow
$69,500,000
Enterprise Value
$3,232,869,376
Total Cash
$185,500,000
Total Debt
$812,600,000
Shares Out
218,056,016
Trailing EPS
$-0.04
Book Value
$9.61
ROE
-0.4%
ROA
-0.4%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
May 2026 870,400,000 -21,600,000 -7,900,000 3,346,000,000 1,253,100,000 83,200,000
May 2025 894,661,000 -1,676,000 -1,092,044,000 3,443,836,000 1,372,582,000 58,244,000
May 2024 924,222,000 58,663,000 -9,421,000 4,548,833,000 1,404,691,000 35,264,000
May 2023 822,447,000 37,515,000 -22,870,000 4,554,432,000 1,420,215,000 41,028,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$0.38

Max Pain — expiry 2026-12-18

max pain strike: $7.50 · spot: $11.60 · call oi: 0 · put oi: 1,323

Peers — same industry

TickerNameMarket CapLastDaily %
CLDX Celldex Therapeutics, Inc. $3.19B $40.57
NTLA Intellia Therapeutics, Inc. $1.76B $12.56
ABSI Absci Corp $1.52B $8.84
QDEL QuidelOrtho Corp $993.66M $14.49
LNTH Lantheus Holdings, Inc. $6.58B $100.80

News headlines (Yahoo Finance, 1h cache)

Neogen (NEOG) Q4 2026 Earnings Call Transcript
2026-08-08 02:16 · Yahoo
Can Neogen (NEOG) Justify Its Valuation On Earnings And Fiscal 2027 Guidance?
2026-08-02 03:14 · Yahoo
Neogen’s (NEOG) R&D Push and Genomics Sale: Smart Capital Allocation or Margin Risk?
2026-08-01 18:08 · Yahoo
Neogen Corp (NEOG) (Q4 2026) Earnings Call Highlights: Strong Revenue Growth Amidst FX ...
2026-07-30 19:03 · Yahoo
Neogen (NEOG) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
2026-07-30 13:30 · Yahoo
Neogen (NEOG) Beats Q4 Earnings and Revenue Estimates
2026-07-30 12:35 · Yahoo
Neogen Reports Fourth Quarter and Full Fiscal Year 2026 Financial Results
2026-07-30 11:00 · Yahoo
Neogen (NEOG) is a Great Momentum Stock: Should You Buy?
2026-08-24 16:00 · Yahoo
SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER
2026-08-19 20:30 · Yahoo
3 Inflated Stocks Walking a Fine Line
2026-08-19 13:26 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.